2-year maintenance of response with tralokinumab in moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial

被引：0
|
作者：
Blauvelt, A. [1 ]
Lacour, J. -P. [2 ]
Toth, D. [3 ]
Langley, R. [4 ]
Warren, R. [5 ,6 ]
Pinto, P. Herranz [7 ]
Pink, A. [8 ]
Simpson, Eric [9 ]
Peris, Ketty [10 ]
Wollenberg, Andreas [11 ]
Le Gjerum [12 ]
Fangel, Stine [12 ]
Corriveau, Josh [13 ]
Schneider, Shannon [13 ]
Reich, Kristian [14 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Univ Hosp Nice Cote Dazur, Nice, France
[3] Prob Med Res, Windsor, ON, Canada
[4] Dalhousie Univ, Halifax, NS, Canada
[5] Univ Manchester, Dermatol Ctr, Salford Royal NHS Fdn Trust, Salford, Lancs, England
[6] Univ Manchester, NIHR Biomed Res Ctr, Salford, Lancs, England
[7] Hosp Univ La Paz, Dept Dermatol, Madrid, Spain
[8] Guys & St Thomas Hosp, St Johns Inst Dermatol, London, England
[9] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR USA
[10] Univ Cattolica Sacro Cuore, Inst Dermatol, Rome, Italy
[11] Ludwig Maximilian Univ Munich, Munich, Germany
[12] LEO Pharma AS, Ballerup, Denmark
[13] LEO Pharma, Madison, NJ USA
[14] Univ Med Ctr Hamburg Eppendorf, Translat Res Inflammatory Skin Dis, Inst Hlth Serv Res Dermatol & Nursing, Hamburg, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2022年 / 186卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
615
引用
收藏
页码：E143 / E144
页数：2
相关论文
共 50 条
  • [1] Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial
    Blauvelt, Andrew
    Langley, Richard G.
    Lacour, Jean-Philippe
    Toth, Darryl
    Laquer, Vivian
    Beissert, Stefan
    Wollenberg, Andreas
    Herranz, Pedro
    Pink, Andrew E.
    Peris, Ketty
    Fangel, Stine
    Gjerum, Le
    Corriveau, Joshua
    Saeki, Hidehisa
    Warren, Richard B.
    Simpson, Eric
    Reich, Kristian
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (04) : 815 - 824
  • [2] Long-term safety and efficacy of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: an interim analysis of ECZTEND
    Simpson, Eric
    Paller, Amy
    Wollenberg, Andreas
    Bewley, Anthony
    Cork, Michael
    Hong, Chih-Ho
    Soong, Weily
    Almgren, Peter
    Carlsson, Anna
    Blauvelt, Andrew
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB190 - AB190
  • [3] Long-term improvements observed in tralokinumab-treated patients with moderate-to-severe atopic dermatitis: an ECZTEND interim analysis
    Blauvelt, A.
    Lacour, J. -P.
    Toth, D.
    Laquer, V.
    Beissert, S.
    Wollenberg, A.
    Herranz, P.
    Pink, A.
    Peris, K.
    Fangel, S.
    Saeki, H.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E112 - E113
  • [4] EFFICACY OF DUPILUMAB IN A 5-YEAR OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Beck, L.
    Deleuran, M.
    Gonzalez, T.
    Xiao, J.
    Avetisova, E.
    Dubost-Brama, A.
    Shabbir, A.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S90 - S91
  • [5] SAFETY OF DUPILUMAB IN A 5-YEAR OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Beck, L.
    Deleuran, M.
    Sierka, D.
    Coleman, A.
    Gherardi, G.
    Avetisova, E.
    Dubost-Brama, A.
    Shabbir, A.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S92 - S92
  • [6] Long-Term Improvement in Patients with moderate to severe atopic Dermatitis treated with Tralokinumab: An ECZTEND Interim Analysis
    Beissert, Stefan
    Blauvelt, Andrew
    Lacour, Jean-Philippe
    Toth, Darryl
    Laquer, Vivian
    Herranz, Pedro
    Pink, Andrew
    Peris, Ketty
    Fangel, Stine
    Saeki, Hidehisa
    Wollenberg, Andreas
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 29 - 30
  • [7] Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension
    Cork, M. J.
    Thaci, D.
    Eichenfield, L. F.
    Arkwright, P. D.
    Hultsch, T.
    Davis, J. D.
    Zhang, Y.
    Zhu, X.
    Chen, Z.
    Li, M.
    Ardeleanu, M.
    Teper, A.
    Akinlade, B.
    Gadkari, A.
    Eckert, L.
    Kamal, M. A.
    Ruddy, M.
    Graham, N. M. H.
    Pirozzi, G.
    Stahl, N.
    DiCioccio, A. T.
    Bansal, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (01) : 85 - 96
  • [8] Efficacy and safety of switching from dupilumab to upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension trial
    Blauvelt, A.
    Ladizinski, B.
    Prajapati, V. H.
    Laquer, V.
    Fischer, A.
    Eisman, S.
    Wu, T.
    Vigna, N.
    Teixeira, H. D.
    Liu, J.
    Eyerich, K.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E142 - E142
  • [9] COVID-19 in tralokinumab-treated patients with moderate-to-severe atopic dermatitis: case series from the ECZTEND long-term extension trial
    Blauvelt, A.
    Pink, A.
    Worm, M.
    Langley, R.
    Costanzo, A.
    Gjerum, L.
    Jorgensen, E.
    Corriveau, J.
    Guttman-Yassky, E.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E109 - E110
  • [10] Long-Term Efficacy Of Dupilumab In Adults With Moderate-to-Severe Atopic Dermatitis: Results From A 5-Year Open-Label Extension Trial
    Beck, Lisa
    Bissonnette, Robert
    Deleuran, Mette
    Nakahara, Take-shi
    Galus, Ryszard
    Xiao, Jing
    Avetisova, Elena
    Du-bost-Brama, Ariane
    Shabbir, Arsalan
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB5 - AB5
12345